[Intraperitoneal administration of FT-207 for mouse peritonitis carcinomatosa].
The peritoneal surface of the lesion was observed after treatment by scanning electron microscopy to evaluate the anticancer effect of FT-207. FT-207 (1.0 mg/day) was injected intraperitoneally to the DDN mice in which 3 X 10(7) MM2 tumor cells were inoculated the day before treatment. The anticancer effect was examined from 2nd to 7th consecutive day after tumor cell implantation, and the following results were obtained. 1) In the early phase after injection of FT-207, many macrophage-like cells were observed on the peritoneal surface. 2) Each MM2 tumor cell was covered by many macrophage-like cells, and these tumor cells were destroyed. 3) In the late phase after injection of FT-207, tumor cells were hyperplastic on the peritoneal surface, but less prominent than in the control group. 4) Effusion and adhesion in peritonitis carcinomatosa of FT-207 group were less than in the control group.
D000818:Animals; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy* / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D005472:Fluorouracil / Q000031:analogs & derivatives*; D007274:Injections, Intraperitoneal; D008264:Macrophages / Q000648:ultrastructure; D051379:Mice; D008855:Microscopy, Electron, Scanning; D010538:Peritonitis / Q000188:drug therapy* / Q000473:pathology; D005641:Tegafur / Q000008:administration & dosage* / Q000494:pharmacology
D005641:Tegafur; D005472:Fluorouracil